Position of the Transparency Council – Remsima (infliximab)
At its meeting on 24 February 2025, the Transparency Council adopted position No. 27/2025 on the evaluation of the drug Remsima (infliximab) under the drug program B.32. “Treatment of patients with Crohn’s disease (ICD-10 K50)”
Publication of the position >>